Intralipid Related Effect on NKcells in Patients With Unexplained Recurrent Spontaneous Abortion

Intralipid Related Effect on NKcells in Patients With Unexplained Recurrent Spontaneous Abortions

Status

UNKNOWN

Phases

Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT03132779

Enrollment

Registered

2017-04-28

Start date

2017-05-01

Completion date

2018-02-20

Last updated

2017-04-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Recurrent Miscarriage

Keywords

Intralipid, NK cells, Recurrent miscarriage

Brief summary

Evaluating the effect of intralipid on the natural killer cells

Detailed description

This study will done on women with recurrent spontaneous abortions having increased NKCELLS activity and evaluate the effect of Intralipid on them after re-estimation of NKcells activity again after one week of Intralipid adminstration

Interventions

DRUGIntralipid

Adose of intralipid given and rechecking NKcells activity

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Intervention model description

Women with unexplained recurrent spontaneous abortions having increased NKcells activity

Eligibility

Sex/Gender

FEMALE

Age

18 Years to 38 Years

Healthy volunteers

Yes

Inclusion criteria

* All women icluded having recurrent spontaneous abortions equal or more than twice. * Alittle women having increased NKCELLS activity.

Exclusion criteria

* Any other diseases causing miscarriage as autoimmune (lupus erythematosus or antiphospholipid antibodies syndrome )or endocrinopathy (diabetes mellitus, thyroid disorders and hyperprolactinaemia)or thrombophilia (factor v leiden mutation, protein c or s deficiency, prothrombin G20210A mutation, antithrombin III deficiency ) or abnormal karyotyping to one or both of parents or previous history of hormonal contraception or intrauterine device usage at last 3 months or any contraindications for intralipid usage.

Design outcomes

Primary

Measure	Time frame	Description
Change in NK cells activity after injection of intralipid	One week	NK cells is measured before and after injection of intralipid and is noticed for change in activity

Contacts

Primary ContactSobhy R Mohammed, MBBCH

Garavandya@hotmail.com01003815460

Backup ContactAhmed M BahaaEldin, MD

abaha0503@yahoo.com01111700556

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026